Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Dr Reddy’s Laboratories ( (RDY) ).
On September 10, 2025, Dr. Reddy’s Laboratories announced the acquisition of the STUGERON® brand from Janssen Pharmaceutica NV, an affiliate of Johnson & Johnson. This acquisition, valued at USD 50.5 million, includes the STUGERON® portfolio across 18 markets in the APAC and EMEA regions, with India and Vietnam as key markets. The acquisition strengthens Dr. Reddy’s Central Nervous System (CNS) portfolio by expanding into the anti-vertigo segment, leveraging STUGERON®’s leading position in the Cinnarizine market in India. This strategic move aligns with Dr. Reddy’s broader goal of enhancing patient access and aims to reach over 1.5 billion patients by 2030.
The most recent analyst rating on (RDY) stock is a Buy with a $16.00 price target. To see the full list of analyst forecasts on Dr Reddy’s Laboratories stock, see the RDY Stock Forecast page.
Spark’s Take on RDY Stock
According to Spark, TipRanks’ AI Analyst, RDY is a Outperform.
Dr Reddy’s Laboratories exhibits strong financial health and strategic growth initiatives, which are offset by challenges in the U.S. generics market and declining gross profit margins. The technical analysis suggests stability, while the valuation is fair. The earnings call provided a mixed outlook, balancing growth with market challenges.
To see Spark’s full report on RDY stock, click here.
More about Dr Reddy’s Laboratories
Dr. Reddy’s Laboratories Ltd. is a global pharmaceutical company headquartered in Hyderabad, India, established in 1984. The company is committed to providing access to affordable and innovative medicines, offering a portfolio that includes APIs, generics, branded generics, biosimilars, and OTC products. Its major therapeutic areas include gastrointestinal, cardiovascular, diabetology, oncology, pain management, and dermatology, with significant markets in the USA, India, Russia & CIS countries, China, Brazil, and Europe.
Average Trading Volume: 1,295,321
Technical Sentiment Signal: Strong Buy
Current Market Cap: $12.35B
For detailed information about RDY stock, go to TipRanks’ Stock Analysis page.